Literature DB >> 6645797

Molecular forms of cholecystokinin in human plasma during infusion of bombesin.

J B Jansen, C B Lamers.   

Abstract

Bombesin is a tetradecapeptide with stimulatory actions on several gastrointestinal functions. Infusion of bombesin (60 pmol/kg. 20 min) into 7 normal subjects induced significant increases in plasma cholecystokinin (CCK) as measured with 2 sequence-specific radioimmunoassays. Employing antibody 1703, specific for carboxyl-terminal CCK-peptides containing at least 14 amino acid residues, plasma CCK concentrations rose from 0.8 +/- 0.2 pmol/l to 9.9 +/- 1.7 pmol/l (p less than 0.005), while using antibody T204, specific for the sulfated tyrosine region of CCK, plasma CCK levels increased from 2.9 +/- 0.5 pmol/l to 12.4 +/- 1.3 pmol/l (p less than 0.005). Plasma samples obtained from 3 subjects during bombesin infusion were fractionated by Sephadex column chromatography. Fractionation revealed 4 molecular forms of CCK: peak I eluted in the void volume and comprised 0-7% of CCK-like immunoreactivity, peak II eluted at 35% and comprised 8-41% of CCK-like immunoreactivity, peak III eluted at 50% and comprised 44-61% of CCK-like immunoreactivity, and peak IV eluted at 75% and comprised 15-27% of CCK-like immunoreactivity. Radioimmunoassay with a carboxyl-terminal CCK-antibody fully cross-reacting with gastrin did not reveal additional molecular forms of CCK. Since both the carboxyl-terminus and the sulfated tyrosine region are required for biological activity of CCK, it is likely that all these molecular forms of CCK possess biological activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6645797     DOI: 10.1016/0024-3205(83)90291-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  9 in total

1.  Plasma cholecystokinin and gallbladder responses to increasing doses of bombesin in celiac disease.

Authors:  P W Thimister; W P Hopman; G Rosenbusch; J B Jansen
Journal:  Dig Dis Sci       Date:  1998-03       Impact factor: 3.199

2.  Plasma cholecystokinin response to oral fat in patients with Billroth I and Billroth II gastrectomy.

Authors:  W P Hopman; J B Jansen; C B Lamers
Journal:  Ann Surg       Date:  1984-03       Impact factor: 12.969

3.  Plasma cholecystokinin response to a liquid fat meal in vagotomized patients.

Authors:  W P Hopman; J B Jansen; C B Lamers
Journal:  Ann Surg       Date:  1984-12       Impact factor: 12.969

4.  Release of cholecystokinin and gallbladder contraction before and after gastrectomy.

Authors:  K Inoue; A Fuchigami; R Hosotani; M Kogire; Y S Huang; T Miyashita; T Suzuki; K Tsuda; Y Seino; P L Rayford
Journal:  Ann Surg       Date:  1987-01       Impact factor: 12.969

5.  Plasma cholecystokinin and gallbladder responses to intraduodenal fat in gallstone patients.

Authors:  A A Masclee; J B Jansen; W M Driessen; L M Geuskens; C B Lamers
Journal:  Dig Dis Sci       Date:  1989-03       Impact factor: 3.199

6.  Pancreatic enzyme response to a liquid meal and to hormonal stimulation. Correlation with plasma secretin and cholecystokinin levels.

Authors:  C Beglinger; M Fried; I Whitehouse; J B Jansen; C B Lamers; K Gyr
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

7.  Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.

Authors:  M C Jebbink; J B Jansen; A A Masclee; C B Lamers
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

8.  Plasma cholecystokinin concentrations in patients with pancreatic insufficiency measured by sequence-specific radioimmunoassays.

Authors:  J B Jansen; W P Hopman; C B Lamers
Journal:  Dig Dis Sci       Date:  1984-12       Impact factor: 3.199

9.  Effects of cisapride on gallbladder emptying and pancreatic polypeptide and cholecystokinin release in humans.

Authors:  T Meguro; T Shimosegawa; Y Kikuchi; M Koizumi; T Toyota
Journal:  J Gastroenterol       Date:  1995-04       Impact factor: 7.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.